Rivaroxaban 10 MG

DRUG19 trials

Conditions

Aortic RegurgitationAortic StenosisArthroplastyAtrial FibrillationBleedingCOVID-19CancerCentral Venous Catheter Thrombosis

Phase 1

Rivaroxaban in Bariatric Surgery

CompletedNCT02438098

Insel Gruppe AG, University Hospital BernProphylaxis of Venous Thromboembolism

Start: 2015-06-30End: 2015-11-30Updated: 2016-01-08

PK of Rivaroxaban in Bariatric Patients - Extension

CompletedNCT02832947

Insel Gruppe AG, University Hospital BernProphylaxis of Venous Thromboembolism

Start: 2016-02-29End: 2016-10-31Updated: 2017-04-11

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

CompletedNCT03083704

Portola PharmaceuticalsBleeding

Start: 2017-02-26End: 2017-09-28Updated: 2023-08-08

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

CompletedNCT03282643

Capital Medical UniversityNeoplasms

Start: 2016-02-16End: 2019-04-01Updated: 2019-04-16

Phase 2

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

RecruitingNCT05920343

Ottawa Hospital Research InstituteUrologic Cancer, Venous Thromboembolism

Start: 2024-11-04End: 2026-10-31Target: 120Updated: 2025-07-10

Phase 3

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

CompletedNCT01830543

Janssen Scientific Affairs, LLCAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2013-05-10End: 2016-07-28Updated: 2017-09-19

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

CompletedNCT03506815

Ottawa Hospital Research InstituteCancer, Central Venous Catheter Thrombosis, Upper Extremity Deep Vein Thrombosis

Start: 2019-03-15End: 2020-06-14Updated: 2024-07-05

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

CompletedNCT04662684

Science Valley Research InstituteCovid19, Venous Thromboembolism

Start: 2020-10-16End: 2021-08-30Updated: 2022-04-06

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

RecruitingNCT05029063

Ottawa Hospital Research InstituteCancer, Venous Thromboembolism

Start: 2022-10-05End: 2027-12-31Target: 1828Updated: 2025-07-09

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

TerminatedNCT05033314

University Health Network, TorontoCentral Venous Catheter Thrombosis, Sickle Cell Disease, Venous Thromboembolism

Start: 2022-06-07End: 2024-10-01Updated: 2025-03-19

RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing

RecruitingNCT06195540

University Hospital, AngersDeep Vein Thrombosis, Immobilisation, Lower Limb Trauma +3

Start: 2024-07-19End: 2026-11-19Target: 1424Updated: 2025-12-08

Phase 4

Dose-finding of Rivaroxaban in Hemodialysis

CompletedNCT02047006

AZ Sint-Jan AVChronic Renal Failure

Start: 2013-09-30End: 2014-10-31Updated: 2015-01-14

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

NCT02974920

Christian Torp-PedersenAortic Regurgitation, Aortic Stenosis, Thrombosis

Start: 2017-01-01End: 2022-11-30Target: 1000Updated: 2018-06-27

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

TerminatedNCT03196349

Duke UniversityVenous Thromboembolism

Start: 2018-08-01End: 2019-05-01Updated: 2019-12-13

COVID-19 Antithrombotic Rivaroxaban Evaluation

TerminatedNCT04757857

Hospital Alemão Oswaldo CruzCOVID-19

Start: 2020-09-29End: 2022-08-30Updated: 2023-01-25

Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer

NCT05303818

Hospital do Servidor Publico EstadualColonic Cancer, Deep Venous Thrombosis

Start: 2022-06-01End: 2024-06-01Target: 68Updated: 2022-03-31

Rivaroxaban in Idiopathic Membranous Nephropathy

RecruitingNCT07404436

Beijing Friendship HospitalIdiopathic Membranous Nephropathy

Start: 2024-01-05End: 2026-12-31Target: 134Updated: 2026-02-11

Unknown Phase

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

NCT05449327

Chiayi Christian HospitalArthroplasty, Venous Thromboembolism

Start: 2023-02-01End: 2025-12-21Target: 178Updated: 2023-10-03

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

NCT06196918

Nanfang Hospital, Southern Medical UniversityGlioma, Malignant

Start: 2023-11-01End: 2025-02-28Target: 320Updated: 2024-01-09

2025-12-011 citations

THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol

BMJ Open2024-01-014 citations

Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.

2023-05-1812 citations

Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).

2023-03-011 citations

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.

2021-12-15177 citations

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

Journal of the American Heart Association2021-11-1012 citations

Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial.

2021-05-0511 citations

Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.

2020-01-0135 citations

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Circulation Cardiovascular Interventions2019-11-013 citations

Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.

2019-05-018 citations

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2019-02-0111 citations

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

2018-10-0110 citations

Pilot trials in thrombosis: Purpose and pitfalls

Research and Practice in Thrombosis and Haemostasis2018-06-135 citations

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

2018-03-1424 citations

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Circulation2016-11-1595 citations

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

New England Journal of Medicine2016-11-141525 citations

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

2014-12-20102 citations